Prime Medicine CFO buys 20,000 shares at $1.19; stock down 84.7% from 52-week high amid cluster pattern of 2 other insider purchases.
Richard Brudnick, Chief Business Officer of Prime Medicine, purchased 20,000 shares at $1.19 on 2025-05-20, establishing an initial position. The timing follows a broader insider buying pattern: 2 other insiders also acquired shares within the past 14 days, forming a cluster buy. The purchase occurs amid significant price deterioration—the stock has fallen 84.7% from its 52-week high of $8.03 and has declined 58.5% over the past 90 days. The company remains operationally challenged, with a $-51.9M net loss in the most recent fiscal year against only $1.5M in quarterly revenue, limiting the fundamental case for valuation support. The convergence of multiple insider purchases at severely depressed levels warrants attention to whether management views the current price as an inflection point, though the company's negative earnings and revenue scale provide substantial execution risk.